Daniel Heid

Daniel Heid

Auto-generated profile, based on publicly available information

Daniel Heid

Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Baden-Württemberg, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
JTJervis Vermal Thevathasan
Jervis Vermal Thevathasan
MKMaurice Kahnwald
Maurice Kahnwald
KCKonstanty Cieśliński
Konstanty Cieśliński
PHPhilipp Hoess
Philipp Hoess
SPSudheer Kumar Peneti
Sudheer Kumar Peneti
JRJonas Ries
Jonas Ries

21 September 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAlexej Ballhausen
Alexej Ballhausen
MPMoritz Jakob Przybilla
Moritz Jakob Przybilla
MJMichael Jendrusch
Michael Jendrusch
SHSaskia Haupt
Saskia Haupt
EPElisabeth Pfaffendorf
Elisabeth Pfaffendorf
MKMatthias Kloor
Matthias Kloor
The immune system can recognize and attack cancer cells, especially those with a high load of mutation-induced neoantigens. Such neoantigens are abundant in DNA mismatch repair (MMR)-deficient, microsatellite-unstable (MSI) cancers. MMR deficiency leads to insertion/deletion (indel) mutations at coding microsatellites (cMS) and to neoantigen-inducing translational frameshifts. Here, we develop a tool to quantify frameshift mutations in MSI colorectal and endometrial cancer. Our results show that frameshift mutation frequency is negatively correlated to the predicted immunogenicity of the resulting peptides, suggesting counterselection of cell clones with highly immunogenic frameshift peptides. This correlation is absent in tumors with Beta-2-microglobulin mutations, and HLA-A*02:01 status is related to cMS mutation patterns. Importantly, certain outlier mutations are common in MSI cancers despite being related to frameshift peptides with functionally confirmed immunogenicity, suggesting a possible driver role during MSI tumor evolution. Neoantigens resulting from shared mutations represent promising vaccine candidates for prevention of MSI cancers.

15 December 2022 in Blood
Verified
Journal Article
Closed access
PDF file
MJMaike Janssen
Maike Janssen
CSChristina Schmidt
Christina Schmidt
PBPeter-Martin Bruch
Peter-Martin Bruch
MBMaximilian Felix Blank
Maximilian Felix Blank
CRChristian Rohde
Christian Rohde
SDSascha Dietrich
Sascha Dietrich
BCL-2 inhibition has been shown to be effective in acute myeloid leukemia (AML) in combination with hypomethylating agents or low-dose cytarabine. However, resistance and relapse represent major clinical challenges. Therefore, there is an unmet need to overcome resistance to current venetoclax-based strategies. We performed high-throughput drug screening to identify effective combination partners for venetoclax in AML. Overall, 64 antileukemic drugs were screened in 31 primary high-risk AML samples with or without venetoclax. Gilteritinib exhibited the highest synergy with venetoclax in FLT3 wild-type AML. The combination of gilteritinib and venetoclax increased apoptosis, reduced viability, and was active in venetoclax-azacitidine–resistant cell lines and primary patient samples. Proteomics revealed increased FLT3 wild-type signaling in specimens with low in vitro response to the currently used venetoclax-azacitidine combination. Mechanistically, venetoclax with gilteritinib decreased phosphorylation of ERK and GSK3B via combined AXL and FLT3 inhibition with subsequent suppression of the antiapoptotic protein MCL-1. MCL-1 downregulation was associated with increased MCL-1 phosphorylation of serine 159, decreased phosphorylation of threonine 161, and proteasomal degradation. Gilteritinib and venetoclax were active in an FLT3 wild-type AML patient-derived xenograft model with TP53 mutation and reduced leukemic burden in 4 patients with FLT3 wild-type AML receiving venetoclax-gilteritinib off label after developing refractory disease under venetoclax-azacitidine. In summary, our results suggest that combined inhibition of FLT3/AXL potentiates venetoclax response in FLT3 wild-type AML by inducing MCL-1 degradation. Therefore, the venetoclax-gilteritinib combination merits testing as a potentially active regimen in patients with high-risk FLT3 wild-type AML.

19 May 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KRKevin Roehle
Kevin Roehle
LQLi Qiang
Li Qiang
KVKatherine S. Ventre
Katherine S. Ventre
DHDaniel Heid
Daniel Heid
LALestat R. Ali
Lestat R. Ali
SDStephanie K. Dougan
Stephanie K. Dougan
Loss of major histocompatibility complex (MHC) class I and interferon-γ (IFN-γ) sensing are major causes of primary and acquired resistance to checkpoint blockade immunotherapy. Thus, additional treatment options are needed for tumors that lose expression of MHC class I. The cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2) regulate classical and alternative nuclear factor κB (NF-κB) signaling. Induction of noncanonical NF-κB signaling with cIAP1/2 antagonists mimics costimulatory signaling, augmenting antitumor immunity. We show that induction of noncanonical NF-κB signaling induces T cell–dependent immune responses, even in β2-microglobulin (β2M)–deficient tumors, demonstrating that direct CD8 T cell recognition of tumor cell–expressed MHC class I is not required. Instead, T cell–produced lymphotoxin reprograms both mouse and human macrophages to be tumoricidal. In wild-type mice, but not mice incapable of antigen-specific T cell responses, cIAP1/2 antagonism reduces tumor burden by increasing phagocytosis of live tumor cells. Efficacy is augmented by combination with CD47 blockade. Thus, activation of noncanonical NF-κB stimulates a T cell–macrophage axis that curtails growth of tumors that are resistant to checkpoint blockade because of loss of MHC class I or IFN-γ sensing. These findings provide a potential mechanism for controlling checkpoint blockade refractory tumors.

13 May 2019 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
JBJulius Upmeier zu Belzen
Julius Upmeier zu Belzen
TBThore Bürgel
Thore Bürgel
SHStefan Holderbach
Stefan Holderbach
FBFelix Bubeck
Felix Bubeck
LALukas Adam
Lukas Adam
RERoland Eils
Roland Eils

13 November 2025 in Blood
Verified
Journal Article
Open access
CPCornelius Pauli
Cornelius Pauli
MKMichael Kienhöfer
Michael Kienhöfer
MBMaximilian Felix Blank
Maximilian Felix Blank
OBOguzhan Begik
Oguzhan Begik
CRChristian Rohde
Christian Rohde
MFMichaela Frye
Michaela Frye
Dysregulated RNA modifications contribute to cancer progression and therapy resistance, yet the underlying mechanism often remains unknown. Here, we perform CRISPR-based synthetic lethality screens to systematically explore the role of RNA modifications in mediating resistance to antileukemic drugs. We identify the tRNA methyltransferase 5 (TRMT5)–mediated formation of N1-methylguanosine (m1G) in the transfer RNA (tRNA) anticodon loop as essential for mediating drug tolerance to cytarabine and venetoclax (Ven) in acute myeloid leukemia (AML). TRMT5 methylates nearly all mitochondrial and nuclear tRNAs with a guanosine at position 37, but its role in promoting drug tolerance specifically depends on its mitochondrial function. TRMT5 is essential for the dynamic upregulation of mitochondrial messenger RNA translation and oxidative phosphorylation, which are critical for sustaining drug tolerance in leukemia cells. This mitochondrial dependency correlates with therapy outcomes in patients with leukemia: lower expression of electron transport chain genes is linked to poorer outcomes in a cohort of nearly 100 patients with AML undergoing first induction therapy. Finally, we demonstrate that targeted depletion of the TRMT5 protein using a conditional degron, in conjunction with cytarabine and Ven treatment, synergistically induces cell death in drug-tolerant AML cells. Thus, our study reveals TRMT5 as a promising drug target for therapy-resistant leukemia.